AIMS/HYPOTHESIS: Fibrinogen and elevated AER increase cardiovascular mortality, but few data are available in the type 2 diabetic population. We have conducted an 11-year follow-up study of the Casale Monferrato cohort to assess: (1) the long-term predictive role of AER independently of conventional risk factors; (2) the shape of its relationship with cardiovascular mortality; and (3) whether fibrinogen has a predictive effect independent of the increased cardiovascular risk associated with nephropathy. METHODS: During the follow-up period (1991-2001) a population-based cohort of 1,565 patients was regularly examined, and measurements of HbA1c were centralised. Multivariate Cox proportional hazards modelling was employed to assess the role of fibrinogen and AER as predictors of all-cause and cardiovascular mortality, independently of baseline variables and individual cumulative average values of HbA1c during follow-up. RESULTS: In 10,890.2 person-years of observations, 685 deaths were identified, giving an all-cause mortality rate of 63.4 per 1,000 person-years (95% CI 58.8-68.3). In Cox regression analyses, the strongest predictor of cardiovascular mortality was macroalbuminuria (relative risk 2.18, 95% CI 1.62-2.94), which was mainly associated with a high risk of short-term mortality. No increased risk was evident until the upper microalbuminuric range of AER values. Plasma fibrinogen was also a major independent predictor, and its role was not modified by AER, or by the exclusion of subjects developing chronic renal failure or diabetic nephropathy during follow-up. CONCLUSIONS/ INTERPRETATION: The results indicate that: (1) AER is the main independent predictor of 11-year cardiovascular mortality; (2) this effect is mainly evident in the upper range of microalbuminuria and in macroalbuminuria; and (3) fibrinogen has an independent effect on cardiovascular mortality, but no synergistic effect with AER, suggesting that both endothelial dysfunction and chronic inflammation are involved in the excess cardiovascular mortality of type 2 diabetic patients.
AIMS/HYPOTHESIS: Fibrinogen and elevated AER increase cardiovascular mortality, but few data are available in the type 2 diabetic population. We have conducted an 11-year follow-up study of the Casale Monferrato cohort to assess: (1) the long-term predictive role of AER independently of conventional risk factors; (2) the shape of its relationship with cardiovascular mortality; and (3) whether fibrinogen has a predictive effect independent of the increased cardiovascular risk associated with nephropathy. METHODS: During the follow-up period (1991-2001) a population-based cohort of 1,565 patients was regularly examined, and measurements of HbA1c were centralised. Multivariate Cox proportional hazards modelling was employed to assess the role of fibrinogen and AER as predictors of all-cause and cardiovascular mortality, independently of baseline variables and individual cumulative average values of HbA1c during follow-up. RESULTS: In 10,890.2 person-years of observations, 685 deaths were identified, giving an all-cause mortality rate of 63.4 per 1,000 person-years (95% CI 58.8-68.3). In Cox regression analyses, the strongest predictor of cardiovascular mortality was macroalbuminuria (relative risk 2.18, 95% CI 1.62-2.94), which was mainly associated with a high risk of short-term mortality. No increased risk was evident until the upper microalbuminuric range of AER values. Plasma fibrinogen was also a major independent predictor, and its role was not modified by AER, or by the exclusion of subjects developing chronic renal failure or diabetic nephropathy during follow-up. CONCLUSIONS/ INTERPRETATION: The results indicate that: (1) AER is the main independent predictor of 11-year cardiovascular mortality; (2) this effect is mainly evident in the upper range of microalbuminuria and in macroalbuminuria; and (3) fibrinogen has an independent effect on cardiovascular mortality, but no synergistic effect with AER, suggesting that both endothelial dysfunction and chronic inflammation are involved in the excess cardiovascular mortality of type 2 diabeticpatients.
Authors: M Greaves; R G Malia; K Goodfellow; M Mattock; L K Stevens; J M Stephenson; J H Fuller Journal: Diabetologia Date: 1997-06 Impact factor: 10.122
Authors: G Bruno; P Cavallo-Perin; G Bargero; M Borra; N D'Errico; G Macchia; G Pagano Journal: Diabetes Metab Res Rev Date: 2001 Mar-Apr Impact factor: 4.876
Authors: H C Gerstein; J F Mann; Q Yi; B Zinman; S F Dinneen; B Hoogwerf; J P Hallé; J Young; A Rashkow; C Joyce; S Nawaz; S Yusuf Journal: JAMA Date: 2001-07-25 Impact factor: 56.272
Authors: Anthony J G Hanley; Andreas Festa; Ralph B D'Agostino; Lynne E Wagenknecht; Peter J Savage; Russell P Tracy; Mohammed F Saad; Steven M Haffner Journal: Diabetes Date: 2004-07 Impact factor: 9.461
Authors: G Bruno; F Merletti; G Bargero; G Novelli; D Melis; A Soddu; M Perotto; G Pagano; P Cavallo-Perin Journal: Diabetologia Date: 2007-03-02 Impact factor: 10.122
Authors: P L Drury; R Ting; D Zannino; C Ehnholm; J Flack; M Whiting; R Fassett; J-C Ansquer; P Dixon; T M E Davis; C Pardy; P Colman; A Keech Journal: Diabetologia Date: 2010-07-30 Impact factor: 10.122
Authors: M Giordano; P Lucidi; T Ciarambino; L Gesuè; P Castellino; M Cioffi; P Gresele; G Paolisso; P De Feo Journal: Diabetologia Date: 2007-11-17 Impact factor: 10.122
Authors: G Bruno; F Merletti; A Biggeri; G Bargero; S Prina-Cerai; G Pagano; P Cavallo-Perin Journal: Diabetologia Date: 2006-03-09 Impact factor: 10.122
Authors: Carlo Giorda; Roberta Picariello; Elisa Nada; Barbara Tartaglino; Lisa Marafetti; Giuseppe Costa; Roberto Gnavi Journal: PLoS One Date: 2012-04-03 Impact factor: 3.240
Authors: Roberto Gnavi; Roberta Picariello; Ludmi la Karaghiosoff; Giuseppe Costa; Carlo Giorda Journal: Diabetes Care Date: 2009-08-12 Impact factor: 17.152